{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T16:57:06Z","timestamp":1781024226185,"version":"3.54.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,9]]},"DOI":"10.7759\/cureus.110532","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:58:51Z","timestamp":1781020731000},"source":"Crossref","is-referenced-by-count":0,"title":["Beyond Lesion Control: A Narrative Review of Targeted Therapy and Surgical Decision-Making in Children With Vascular Anomalies Across Function, Growth, and Perioperative Care"],"prefix":"10.7759","author":[{"given":"Omer","family":"Altamimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Altamimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahaf","family":"Alhowidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghaida M","family":"Alosaimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman M","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aseel","family":"Ashri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara H","family":"Essa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara F","family":"Aljefri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sultan","family":"Khoja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamar A","family":"Alsaigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulkreem","family":"Al-Juhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/00006534-198203000-00002","article-title":"Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics","volume":"69","author":"Mulliken JB","year":"1982","unstructured":"Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg. 1982, 69:412-22. 10.1097\/00006534-198203000-00002","journal-title":"Plast Reconstr Surg"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-3673","article-title":"Vascular anomalies classification: recommendations from the International Society for the Study of Vascular Anomalies","volume":"136","author":"Wassef M","year":"2015","unstructured":"Wassef M, Blei F, Adams D, et al.. Vascular anomalies classification: recommendations from the International Society for the Study of Vascular Anomalies. Pediatrics. 2015, 136:e203-14. 10.1542\/peds.2014-3673","journal-title":"Pediatrics"},{"key":"ref3","unstructured":"International Society for the Study of Vascular Anomalies. ISSVA classification for vascular anomalies. (2025). Accessed. 18 May 2026: https:\/\/www.issva.org\/classification."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1148\/rg.2016150197","article-title":"2014 revised classification of vascular lesions from the International Society for the Study of Vascular Anomalies: radiologic-pathologic update","volume":"36","author":"Merrow AC","year":"2016","unstructured":"Merrow AC, Gupta A, Patel MN, Adams DM. 2014 revised classification of vascular lesions from the International Society for the Study of Vascular Anomalies: radiologic-pathologic update. Radiographics. 2016, 36:1494-516. 10.1148\/rg.2016150197","journal-title":"Radiographics"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-023-05166-y","article-title":"Health-related quality of life in children with congenital vascular malformations","volume":"182","author":"Bouwman FC","year":"2023","unstructured":"Bouwman FC, Verhaak C, de Blaauw I, et al.. Health-related quality of life in children with congenital vascular malformations. Eur J Pediatr. 2023, 182:5067-77. 10.1007\/s00431-023-05166-y","journal-title":"Eur J Pediatr"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.0002","article-title":"Vascular malformations and health-related quality of life: a systematic review and meta-analysis","volume":"154","author":"Nguyen HL","year":"2018","unstructured":"Nguyen HL, Bonadurer GF 3rd, Tollefson MM. Vascular malformations and health-related quality of life: a systematic review and meta-analysis. JAMA Dermatol. 2018, 154:661-9. 10.1001\/jamadermatol.2018.0002","journal-title":"JAMA Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20429","article-title":"Development of a condition-specific patient-reported outcome measure for measuring symptoms and appearance in vascular malformations: the OVAMA questionnaire","volume":"185","author":"Lokhorst MM","year":"2021","unstructured":"Lokhorst MM, Horbach SE, Young-Afat DA, Stor ML, Haverman L, Spuls PI, van der Horst CM. Development of a condition-specific patient-reported outcome measure for measuring symptoms and appearance in vascular malformations: the OVAMA questionnaire. Br J Dermatol. 2021, 185:797-803. 10.1111\/bjd.20429","journal-title":"Br J Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.23124","article-title":"Sirolimus for the treatment of complicated vascular anomalies in children","volume":"57","author":"Hammill AM","year":"2011","unstructured":"Hammill AM, Wentzel M, Gupta A, et al.. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer. 2011, 57:1018-24. 10.1002\/pbc.23124","journal-title":"Pediatr Blood Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-3257","article-title":"Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies","volume":"137","author":"Adams DM","year":"2016","unstructured":"Adams DM, Trenor CC 3rd, Hammill AM, et al.. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics. 2016, 137:e20153257. 10.1542\/peds.2015-3257","journal-title":"Pediatrics"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2021.04.071","article-title":"A prospective multicenter study of sirolimus for complicated vascular anomalies","volume":"74","author":"Ji Y","year":"2021","unstructured":"Ji Y, Chen S, Yang K, et al.. A prospective multicenter study of sirolimus for complicated vascular anomalies. J Vasc Surg. 2021, 74:1673-81.e3. 10.1016\/j.jvs.2021.04.071","journal-title":"J Vasc Surg"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.3459","article-title":"Sirolimus (rapamycin) for slow-flow malformations in children: the observational-phase randomized clinical PERFORMUS trial","volume":"157","author":"Maruani A","year":"2021","unstructured":"Maruani A, Tavernier E, Boccara O, et al.. Sirolimus (rapamycin) for slow-flow malformations in children: the observational-phase randomized clinical PERFORMUS trial. JAMA Dermatol. 2021, 157:1289-98. 10.1001\/jamadermatol.2021.3459","journal-title":"JAMA Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2023.100969","article-title":"Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS)","volume":"25","author":"Canaud G","year":"2023","unstructured":"Canaud G, Lopez Gutierrez JC, Irvine AD, et al.. Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS). Genet Med. 2023, 25:100969. 10.1016\/j.gim.2023.100969","journal-title":"Genet Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2020.08.051","article-title":"The impact of adjuvant sirolimus therapy in the surgical management of scrotal slow-flow vascular malformations","volume":"147","author":"Szhafir I","year":"2021","unstructured":"Szhafir I, Teplisky D, Lambert G, et al.. The impact of adjuvant sirolimus therapy in the surgical management of scrotal slow-flow vascular malformations. Urology. 2021, 147:270-4. 10.1016\/j.urology.2020.08.051","journal-title":"Urology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpedsurg.2022.11.009","article-title":"No association of sirolimus with wound complications in children with vascular anomalies","volume":"58","author":"Mehl SC","year":"2023","unstructured":"Mehl SC, Whitlock RS, Ortega RM, et al.. No association of sirolimus with wound complications in children with vascular anomalies. J Pediatr Surg. 2023, 58:1555-9. 10.1016\/j.jpedsurg.2022.11.009","journal-title":"J Pediatr Surg"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1253521","article-title":"A step-by-step practical approach to imaging diagnosis and interventional radiologic therapy in vascular malformations","volume":"27","author":"Legiehn GM","year":"2010","unstructured":"Legiehn GM, Heran MK. A step-by-step practical approach to imaging diagnosis and interventional radiologic therapy in vascular malformations. Semin Intervent Radiol. 2010, 27:209-31. 10.1055\/s-0030-1253521","journal-title":"Semin Intervent Radiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.144.7.873","article-title":"Association of localized intravascular coagulopathy with venous malformations","volume":"144","author":"Dompmartin A","year":"2008","unstructured":"Dompmartin A, Acher A, Thibon P, et al.. Association of localized intravascular coagulopathy with venous malformations. Arch Dermatol. 2008, 144:873-7. 10.1001\/archderm.144.7.873","journal-title":"Arch Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00383-020-04727-8","article-title":"An integrated multidisciplinary team approach to the management of vascular anomalies: challenges and benefits","volume":"36","author":"Sires JD","year":"2020","unstructured":"Sires JD, Williams N, Huilgol SC, Harvey I, Antoniou G, Dawson J. An integrated multidisciplinary team approach to the management of vascular anomalies: challenges and benefits. Pediatr Surg Int. 2020, 36:1149-56. 10.1007\/s00383-020-04727-8","journal-title":"Pediatr Surg Int"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2023.113579","article-title":"Vascular anomalies care in the United States: a cross-sectional national survey","volume":"261","author":"Cohen-Cutler S","year":"2023","unstructured":"Cohen-Cutler S, Blatt J, Bayliff S, Iacobas I, Hammill A, Sisk BA. Vascular anomalies care in the United States: a cross-sectional national survey. J Pediatr. 2023, 261:113579. 10.1016\/j.jpeds.2023.113579","journal-title":"J Pediatr"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-1774391","article-title":"Pediatric vascular anomalies: a clinical and radiological perspective","volume":"34","author":"Gupta R","year":"2024","unstructured":"Gupta R, Bhandari A, Navarro OM. Pediatric vascular anomalies: a clinical and radiological perspective. Indian J Radiol Imaging. 2024, 34:103-27. 10.1055\/s-0043-1774391","journal-title":"Indian J Radiol Imaging"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpedsurg.2024.05.019","article-title":"Management and outcomes of pediatric lymphatic malformations: a\u00a0systematic review from the APSA Outcomes and Evidence-Based Practice Committee","volume":"59","author":"Huerta CT","year":"2024","unstructured":"Huerta CT, Beres AL, Englum BR, et al.. Management and outcomes of pediatric lymphatic malformations: a\u00a0systematic review from the APSA Outcomes and Evidence-Based Practice Committee. J Pediatr Surg. 2024, 59:161589. 10.1016\/j.jpedsurg.2024.05.019","journal-title":"J Pediatr Surg"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s00383-022-05320-x","article-title":"Lymphatic malformations in children: retrospective review of surgical and interventional management","volume":"39","author":"Poget M","year":"2022","unstructured":"Poget M, Fresa M, El Ezzi O, Saliou G, Doan MT, de Buys Roessingh A. Lymphatic malformations in children: retrospective review of surgical and interventional management. Pediatr Surg Int. 2022, 39:36. 10.1007\/s00383-022-05320-x","journal-title":"Pediatr Surg Int"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.otohns.2010.02.026","article-title":"Lymphatic malformations: review of current treatment","volume":"142","author":"Perkins JA","year":"2010","unstructured":"Perkins JA, Manning SC, Tempero RM, Cunningham MJ, Edmonds JL Jr, Hoffer FA, Egbert MA. Lymphatic malformations: review of current treatment. Otolaryngol Head Neck Surg. 2010, 142:795-803, 803.e1. 10.1016\/j.otohns.2010.02.026","journal-title":"Otolaryngol Head Neck Surg"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/s0945-053x(01)00150-0","article-title":"Molecular genetics of vascular malformations","volume":"20","author":"Vikkula M","year":"2001","unstructured":"Vikkula M, Boon LM, Mulliken JB. Molecular genetics of vascular malformations. Matrix Biol. 2001, 20:327-35. 10.1016\/s0945-053x(01)00150-0","journal-title":"Matrix Biol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2014.12.069","article-title":"Lymphatic and other vascular malformative\/overgrowth disorders are caused by somatic mutations in PIK3CA","volume":"166","author":"Luks VL","year":"2015","unstructured":"Luks VL, Kamitaki N, Vivero MP, et al.. Lymphatic and other vascular malformative\/overgrowth disorders are caused by somatic mutations in PIK3CA. J Pediatr. 2015, 166:1048-54.e1-5. 10.1016\/j.jpeds.2014.12.069","journal-title":"J Pediatr"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2015.11.011","article-title":"Somatic activating PIK3CA mutations cause venous malformation","volume":"97","author":"Limaye N","year":"2015","unstructured":"Limaye N, Kangas J, Mendola A, et al.. Somatic activating PIK3CA mutations cause venous malformation. Am J Hum Genet. 2015, 97:914-21. 10.1016\/j.ajhg.2015.11.011","journal-title":"Am J Hum Genet"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad9982","article-title":"Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans","volume":"8","author":"Castillo SD","year":"2016","unstructured":"Castillo SD, Tzouanacou E, Zaw-Thin M, et al.. Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans. Sci Transl Med. 2016, 8:332ra43. 10.1126\/scitranslmed.aad9982","journal-title":"Sci Transl Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.857436","article-title":"Indications and limitations of sirolimus in the treatment of vascular anomalies-insights from a retrospective case series","volume":"10","author":"Karastaneva A","year":"2022","unstructured":"Karastaneva A, Gasparella P, Tschauner S, et al.. Indications and limitations of sirolimus in the treatment of vascular anomalies-insights from a retrospective case series. Front Pediatr. 2022, 10:857436. 10.3389\/fped.2022.857436","journal-title":"Front Pediatr"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1304133","article-title":"Clinical effectiveness and safety of sirolimus in pediatric patients with complex vascular anomalies: necessitating personalized and comprehensive approaches","volume":"11","author":"Kim M","year":"2023","unstructured":"Kim M, Hong KT, Park HJ, Kim BK, Choi JY, Kim HY, Kang HJ. Clinical effectiveness and safety of sirolimus in pediatric patients with complex vascular anomalies: necessitating personalized and comprehensive approaches. Front Pediatr. 2023, 11:1304133. 10.3389\/fped.2023.1304133","journal-title":"Front Pediatr"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20212148","article-title":"Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib","volume":"219","author":"Morin G","year":"2022","unstructured":"Morin G, Degrugillier-Chopinet C, Vincent M, et al.. Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib. J Exp Med. 2022, 219:e20212148. 10.1084\/jem.20212148","journal-title":"J Exp Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-37468-4","article-title":"Targeted treatment of severe vascular malformations harboring PIK3CA and TEK mutations with alpelisib is highly effective with limited toxicity","volume":"13","author":"Sterba M","year":"2023","unstructured":"Sterba M, Pokorna P, Faberova R, et al.. Targeted treatment of severe vascular malformations harboring PIK3CA and TEK mutations with alpelisib is highly effective with limited toxicity. Sci Rep. 2023, 13:10499. 10.1038\/s41598-023-37468-4","journal-title":"Sci Rep"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bvth.2025.100133","article-title":"Alpelisib, a PI3K\u03b1 inhibitor, effectively treats vascular anomalies with diverse genotypes and phenotypes","volume":"3","author":"Pithadia DJ","year":"2026","unstructured":"Pithadia DJ, Heskel MJ, Shotayev A, et al.. Alpelisib, a PI3K\u03b1 inhibitor, effectively treats vascular anomalies with diverse genotypes and phenotypes. Blood Vessel Thromb Hemost. 2026, 3:100133. 10.1016\/j.bvth.2025.100133","journal-title":"Blood Vessel Thromb Hemost"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.4653","article-title":"Genotype-guided medical treatment of an arteriovenous malformation in a child","volume":"155","author":"Lekwuttikarn R","year":"2019","unstructured":"Lekwuttikarn R, Lim YH, Admani S, Choate KA, Teng JM. Genotype-guided medical treatment of an arteriovenous malformation in a child. JAMA Dermatol. 2019, 155:256-7. 10.1001\/jamadermatol.2018.4653","journal-title":"JAMA Dermatol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1172\/JCI98589","article-title":"Mosaic RAS\/MAPK variants cause sporadic vascular malformations which respond to targeted therapy","volume":"128","author":"Al-Olabi L","year":"2018","unstructured":"Al-Olabi L, Polubothu S, Dowsett K, et al.. Mosaic RAS\/MAPK variants cause sporadic vascular malformations which respond to targeted therapy. J Clin Invest. 2018, 128:1496-508. 10.1172\/JCI98589","journal-title":"J Clin Invest"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-3206","article-title":"Monitoring arteriovenous malformation response to genotype-targeted therapy","volume":"146","author":"Edwards EA","year":"2020","unstructured":"Edwards EA, Phelps AS, Cooke D, Frieden IJ, Zapala MA, Fullerton HJ, Shimano KA. Monitoring arteriovenous malformation response to genotype-targeted therapy. Pediatrics. 2020, 146:e20193206. 10.1542\/peds.2019-3206","journal-title":"Pediatrics"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2024000599","article-title":"Targeted medical therapies for vascular anomalies","volume":"2024","author":"Borst A","year":"2024","unstructured":"Borst A. Targeted medical therapies for vascular anomalies. Hematology Am Soc Hematol Educ Program. 2024, 2024:709-17. 10.1182\/hematology.2024000599","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae213","article-title":"Responsiveness of the condition-specific Outcome measures for VAscular MAlformations (OVAMA) questionnaire to measure symptoms and appearance in patients with vascular malformations","volume":"191","author":"Stor ML","year":"2024","unstructured":"Stor ML, Lokhorst MM, Horbach SE, Luijten MA, Spuls PI, van der Horst CM. Responsiveness of the condition-specific Outcome measures for VAscular MAlformations (OVAMA) questionnaire to measure symptoms and appearance in patients with vascular malformations. Br J Dermatol. 2024, 191:728-36. 10.1093\/bjd\/ljae213","journal-title":"Br J Dermatol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16029","article-title":"Development of an international core outcome set for peripheral vascular malformations: the OVAMA project","volume":"178","author":"Horbach SE","year":"2018","unstructured":"Horbach SE, van der Horst CM, Blei F, et al.. Development of an international core outcome set for peripheral vascular malformations: the OVAMA project. Br J Dermatol. 2018, 178:473-81. 10.1111\/bjd.16029","journal-title":"Br J Dermatol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0217-9","article-title":"Targeted therapy in patients with PIK3CA-related overgrowth syndrome","volume":"558","author":"Venot Q","year":"2018","unstructured":"Venot Q, Blanc T, Rabia SH, et al.. Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature. 2018, 558:540-6. 10.1038\/s41586-018-0217-9","journal-title":"Nature"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2024.1434493","article-title":"Therapy with sirolimus in vascular anomalies: the experience of two Italian centers on 14 pediatric patients","volume":"12","author":"Neirotti A","year":"2024","unstructured":"Neirotti A, Barat V, Coppo P, et al.. Therapy with sirolimus in vascular anomalies: the experience of two Italian centers on 14 pediatric patients. Front Pediatr. 2024, 12:1434493. 10.3389\/fped.2024.1434493","journal-title":"Front Pediatr"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2024.07.013","article-title":"Targeted treatments for vascular malformations: current state of the art","volume":"22","author":"Seront E","year":"2024","unstructured":"Seront E, Hermans C, Boon LM, Vikkula M. Targeted treatments for vascular malformations: current state of the art. J Thromb Haemost. 2024, 22:2961-75. 10.1016\/j.jtha.2024.07.013","journal-title":"J Thromb Haemost"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1038\/s44321-025-00344-x","article-title":"Vascular malformations: from genetics to therapeutics","volume":"18","author":"Morin G","year":"2026","unstructured":"Morin G, Galasso I, Canaud G. Vascular malformations: from genetics to therapeutics. EMBO Mol Med. 2026, 18:1-21. 10.1038\/s44321-025-00344-x","journal-title":"EMBO Mol Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1089\/lrb.2021.0103","article-title":"Sirolimus in the treatment of microcystic lymphatic malformations: a systematic review","volume":"21","author":"Teng JM","year":"2023","unstructured":"Teng JM, Hammill A, Martini J, Treat J. Sirolimus in the treatment of microcystic lymphatic malformations: a systematic review. Lymphat Res Biol. 2023, 21:101-10. 10.1089\/lrb.2021.0103","journal-title":"Lymphat Res Biol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30758","article-title":"Infectious complications of vascular anomalies treated with sirolimus: a systematic review","volume":"71","author":"Kalbfell R","year":"2024","unstructured":"Kalbfell R, Cohen-Cutler S, Grisham E, et al.. Infectious complications of vascular anomalies treated with sirolimus: a systematic review. Pediatr Blood Cancer. 2024, 71:e30758. 10.1002\/pbc.30758","journal-title":"Pediatr Blood Cancer"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1159\/000533675","article-title":"Indication for a pneumocystis prophylaxis therapy in patients with vascular anomalies treated with PIK3\/AKT\/mTOR pathway inhibitors: experts' opinion and systematic review from the literature","volume":"239","author":"Navarro M","year":"2023","unstructured":"Navarro M, Allemang-Trivalle A, Leducq S, et al.. Indication for a pneumocystis prophylaxis therapy in patients with vascular anomalies treated with PIK3\/AKT\/mTOR pathway inhibitors: experts' opinion and systematic review from the literature. Dermatology. 2023, 239:942-51. 10.1159\/000533675","journal-title":"Dermatology"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvsv.2025.102284","article-title":"Effectiveness and safety of sirolimus in the treatment of venous malformations: a meta-analysis of prospective studies","volume":"13","author":"Wang G","year":"2025","unstructured":"Wang G, Lu W, Zhu Y, Wang C, Yang X. Effectiveness and safety of sirolimus in the treatment of venous malformations: a meta-analysis of prospective studies. J Vasc Surg Venous Lymphat Disord. 2025, 13:102284. 10.1016\/j.jvsv.2025.102284","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvsv.2025.102230","article-title":"A real-world study of sirolimus in the treatment of pediatric head and neck lymphatic malformations","volume":"13","author":"Wang J","year":"2025","unstructured":"Wang J, Meng Y, Zhang X, et al.. A real-world study of sirolimus in the treatment of pediatric head and neck lymphatic malformations. J Vasc Surg Venous Lymphat Disord. 2025, 13:102230. 10.1016\/j.jvsv.2025.102230","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1457614","article-title":"Population pharmacokinetic study in children with vascular anomalies: body weight as a key variable in predicting the initial dose and dosing frequency of sirolimus","volume":"15","author":"Fan L","year":"2024","unstructured":"Fan L, Guo HL, Zhao YT, et al.. Population pharmacokinetic study in children with vascular anomalies: body weight as a key variable in predicting the initial dose and dosing frequency of sirolimus. Front Pharmacol. 2024, 15:1457614. 10.3389\/fphar.2024.1457614","journal-title":"Front Pharmacol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31282","article-title":"Sirolimus for vascular anomalies associated with PTEN hamartoma tumor syndrome","volume":"71","author":"Zabeida A","year":"2024","unstructured":"Zabeida A, Brzezinski JJ, Wasserman JD, et al.. Sirolimus for vascular anomalies associated with PTEN hamartoma tumor syndrome. Pediatr Blood Cancer. 2024, 71:e31282. 10.1002\/pbc.31282","journal-title":"Pediatr Blood Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/500376-beyond-lesion-control-a-narrative-review-of-targeted-therapy-and-surgical-decision-making-in-children-with-vascular-anomalies-across-function-growth-and-perioperative-care","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:58:53Z","timestamp":1781020733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/500376-beyond-lesion-control-a-narrative-review-of-targeted-therapy-and-surgical-decision-making-in-children-with-vascular-anomalies-across-function-growth-and-perioperative-care"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":48,"URL":"https:\/\/doi.org\/10.7759\/cureus.110532","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,9]]}}}